title: [Total antioxidative activity measured by ABTS method in pregnant women treated with L-arginine for IUGR].
abstract: Elevated concentration of free radicals is observed in IUG and it is connected with high rate of prematurity and perinatal mortality too. The total antioxidative serum activity is one of the oxidative stress defence system parameter. The main aim of the study was to find the correlation between the L-arginine therapy and total antioxidative concentration.
  
  
  METHODS
  The study was done in Dep. of Obstetrics and Gynaecology Medical University in Lodz in 2000-20003 y. The study group consist of 45 women with ultrasound diagnosed IUGR, the control group consist of 30 healthy pregnant women at the same gestational age. The IUGR therapy consist of L-arginine 3 x 1 g oral dose daily. The total antioxidative activity was measured in maternal blood on first and 20-th day of treatment. The Wayner method was used to measure total antioxidative activity by reduction of ABTS. The results were expressed in microM of serum.
  
  
  RESULTS
  The value of the total antioxidative activity at the first day of observation in women with IUGR was 225.9 microM and after 20 days increased to 231.8 microM. In women in normal pregnancy at the first day the value was 249.6 ng/ml microM and after 20 days of observation 247.8 microM.
  
  
  CONCLUSIONS
  The total antioxidative activity in blood serum decreased in pregnancy connected with IUGR. The L-arginine treatment decreased the oxidative stress risk.
authors.affiliation: Kliniki Patologii Ciazy Instytutu Ginekologii i Połoznictwa UM w Łodzi.
authors.forename: Agata
authors.initials: A
authors.lastname: Karowicz-Bilińska
authors.forename: Urszula
authors.initials: U
authors.lastname: Kowalska-Koprek
authors.forename: Jacek
authors.initials: J
authors.lastname: Suzin
authors.forename: Piotr
authors.initials: P
authors.lastname: Sieroszewski
mesh_terms: D000328:Adult; D001120:Arginine / Q000008:administration & dosage* / Q000494:pharmacology; D052160:Benzothiazoles; D016022:Case-Control Studies; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D005317:Fetal Growth Retardation / Q000097:blood* / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D007202:Indicators and Reagents; D007231:Infant, Newborn; D009569:Nitric Oxide / Q000097:blood*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects*; D011044:Poland; D011247:Pregnancy; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013451:Sulfonic Acids; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D052160:Benzothiazoles; D007202:Indicators and Reagents; D013451:Sulfonic Acids; C002502:2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid; D009569:Nitric Oxide; D001120:Arginine; D019001:Nitric Oxide Synthase